Final results from the CLEOPATRA study showed that the combination of two targeted agents, trastuzumab and pertuzumab, significantly prolonged survival in patients with HER2-positive advanced breast cancer when compared to trastuzumab alone. This evidence concerns the gene ERBB2 and breast cancer.